How to buy Ultragenyx stock (RARE)

Ultragenyx is a biotechnology business based in the US. Ultragenyx shares (RARE) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $53.82 – a decrease of 1.77% over the previous week. Ultragenyx employs 1,276 staff and has a trailing 12-month revenue of around $481.3 million.

Our top picks for where to buy Ultragenyx stock

Buy Ultragenyx stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Ultragenyx stock price (NASDAQ: RARE)

Use our graph to track the performance of RARE stocks over time.

Ultragenyx shares at a glance

• Key figures

Information last updated 2024-10-24.

Latest market close	$53.82
52-week range	$32.77 - $60.37
50-day moving average more info button	$55.93
200-day moving average more info button	$47.64
Wall St. target price	$91.62
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-7.21

Is it a good time to buy Ultragenyx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ultragenyx price performance over time

Historical closes compared with the close of $53.82 from 2024-10-25

1 week (2024-10-22)	-1.77%
1 month (2024-09-27)	-1.12%
3 months (2024-07-29)	18.97%
6 months (2024-04-29)	22.26%

1 year (2023-10-27)	64.04%
2 years (2022-10-28)	32.04%
3 years (2021-10-29)	83.92
5 years (2019-10-29)	36.29%

Ultragenyx financials

Revenue TTM	$481.3 million
Gross profit TTM	$-370,780,000
Return on assets TTM	-23.42%
Return on equity TTM	-208.43%
Profit margin	-121.57%
Book value	$4.70
Market Capitalization more info button	$5.1 billion

TTM: trailing 12 months

Ultragenyx share dividends

We're not expecting Ultragenyx to pay a dividend over the next 12 months.

Have Ultragenyx's shares ever split?

Ultragenyx's shares were split on a 1:3 basis on 16 January 2014 . So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ultragenyx shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Ultragenyx shares which in turn could have impacted Ultragenyx's share price.

Ultragenyx share price volatility

Over the last 12 months, Ultragenyx's shares have ranged in value from as little as $32.77 up to $60.37. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ultragenyx's is 0.565. This would suggest that Ultragenyx's shares are less volatile than average (for this exchange).

Ultragenyx overview

Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co. , Ltd.

Frequently asked questions

What percentage of Ultragenyx is owned by insiders or institutions?
Currently 3.63% of Ultragenyx shares are held by insiders and 99.25% by institutions. How many people work for Ultragenyx?
Latest data suggests 1,276 work at Ultragenyx. When does the fiscal year end for Ultragenyx?
Ultragenyx's fiscal year ends in December. Where is Ultragenyx based?
Ultragenyx's address is: 60 Leveroni Court, Novato, CA, United States, 94949 What is Ultragenyx's ISIN number?
Ultragenyx's international securities identification number is: US90400D1081 What is Ultragenyx's CUSIP number?
Ultragenyx's Committee on Uniform Securities Identification Procedures number is: 90400D108